Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) (NCT02960555)

🧪 Interventions in This Study

• Isatuximab (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (3 Sites)

• Mount Sinai Hospital — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Smoldering Plasma Cell Myeloma

• Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma — Houston, Texas
• Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma — Duarte, California
• Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients — Duarte, California
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma — Birmingham, Alabama
• Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma — Atlanta, Georgia

Explore by condition: All Smoldering Plasma Cell Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.